Research interests
Diffuse midline gliomas (DMG) are aggressive pediatric brain tumors driven by epigenetic dysregulation, primarily caused by the H3K27M oncohistone mutation or EZHIP (Enhancer of Zeste Homolog Inhibitory Protein) overexpression, both potent inhibitors of PRC2. My project aims to develop a high-sensitivity mass-spectrometry assay to detect H3K27M in liquid biopsies as a minimally invasive diagnostic tool. Additionally, the goal is to investigate how H3K27M and EZHIP remodel chromatin by altering protein interactions and histone PTMs. Through optimized immunoprecipitation workflows, targeted MS measurements and nucleosome-interaction studies, these methods will help clarify how PRC2 inhibition alters chromatin in DMG and may guide the improvement of future diagnostic tools.
